ロード中...
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors in the world. Currently, there are no approved targeted therapies for PDAC. Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are known to be a major driver of PDAC progression, but it was considered an undru...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281596/ https://ncbi.nlm.nih.gov/pubmed/32456277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051341 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|